Key Takeaways Oncology sales rose to over 11% of total revenues, supported by new solid tumor and blood cancer drugs.Newer therapies like Epkinly, Elahere and Emrelis plus Venclexta gains offset declining Imbruvica sales.AbbVie advances other candidates, including pivekimab sunirine and Temab-A, to expand its pipeline.AbbVie (ABBV) has been significantly expanding its presence in the oncology space. What started initially as a two-drug franchise consisting of blood cancer drugs Imbruvica and Venclexta has a ...